Inogen is well-positioned for growth due to strong demand for portable oxygen concentrators, new product launches, and international expansion, though U.S. channel shifts and reimbursement risks remain. The company's shares have declined 16.7% year-to-date, underperforming the S&P 500's 11.2% gain, and it carries a Zacks Rank #3 (Hold). Second-quarter 2026 POC unit volumes rose more than 12% year over year, international revenues increased 15% to $41.3 million, and new products Voxi and Aurora contributed over 100 basis points to growth. However, U.S. sales fell 2% and rental revenues dropped 12% as the shift toward home medical equipment providers pressures direct-to-consumer and rental channels. The Zacks Consensus Estimate for 2026 revenues is $356.7 million, implying 2.3% growth, and the loss per share estimate has narrowed by 3 cents to 74 cents over the past 60 days.
Inogen IncStrong demand for portable oxygen concentrators, with Q2 unit volumes up over 12% and international revenues up 15%.
The Cooper Companies, Inc
Globus Medical
West Pharmaceutical Services Inc